Zymeworks’ stellar Cdata prompts new strategy

Canadian firm Zymeworks (Nasdaq: ZYME), a biotech managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, has announced a new strategy.

The novel strategic initiative will see the company focus on optimizing future cash flows from Ziihera (zanidatamab-hrii), other licensed products and other healthcare assets.

Together with the ability to leverage existing and future R&D partnerships and collaborations through internal innovation, this strategy seeks to optimize a long-term source of growing revenue streams with carefully managed R&D investments to establish a durable, profitable operating structure, Zymeworks says.